2004 Fiscal Year Final Research Report Summary
DEVELOPMENT OF A NEW DETECTION METHOD OF THE MINIMAL RESIDUAL TUMOR CELLS
| Project/Area Number |
15590502
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Single-year Grants |
|---|
| Section | 一般 |
|---|
| Research Field |
Laboratory medicine
|
|---|
| Research Institution | KAWASAKI MEDICAL SCHOOL |
|---|
Principal Investigator |
TOHYAMA Kaoru KAWASAKI MEDICAL SCHOOL, DPT OF LABORATORY MEDICINE, PROFFESOR, 医学部, 教授 (80227561)
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
ITOH Mitsuru KAWASAKI MEDICAL SCHOOL, DPT OF LABORATORY MEDICINE, LECTURER, 医学部, 講師 (00360272)
|
|---|
| Project Period (FY) |
2003 – 2004
|
| Keywords | acute myeloid leukemia / blast / minimal residual tumor cells / flow cytometry / automated hematology analyzer |
|---|
| Research Abstract |
Background : For the diagnosis and therapy of acute leukemia, it is important to detect a small number of leukemic cells precisely. Although several automated hematology analyzers that carry blast-detecting programs have been developed, they do not exert sufficient detection sensitivity to exceed the sensitivity of manual eye counting method. Methods: We constructed a new blast-detecting program by combining the numerical information acquired from five cytometric parameters presented by XE-2100. The sensitivity and specificity of this blast multi-scoring program were assessed in comparison with the‘Blasts' flag program equipped originally in XE-2100.
Results : The blast-detecting sensitivity was found to be highly improved in the blast multi-scoring program as compared with the‘Blasts' flag program without much reducing the specificity. A small number of leukemic myeloblasts were detected at the better sensitivity than the eye counting method in the clinical course of the patients with acute myeloid leukemia (AML).
Conclusions : The daily practical use of this blast multi-scoring program will surely contribute to sensitive, objective and real-time evaluation of the treatment of AML with a low cost.
|
